Cardiovascular

Enoxaparin Shows Safety in Angioplasty - STEEPLE Study

Gilles Montalescot
Gilles Montalescot

The STEEPLE trial randomised more than 3500 elective angioplasty patients to unfractionated heparin or either of two dose levels of enoxaparin. Gilles Montalescot presented the findings in Stockholm and talked about them with Audio Medica.

Click here for all the interviews from ESC 2005

Similar Interviews

  • Audio Journal of Cardiovascular Medicine: Enoxaparin Superior to Unfractionated Heparin for STEMI at 12 months Follow Up: ExTRACT-TIMI 25 Trial">Audio Journal of Cardiovascular Medicine: Enoxaparin Superior to Unfractionated Heparin for STEMI at 12 months Follow Up: ExTRACT-TIMI 25 Trial
  • David Morrow REFERENCE: Abstract 1027, Clinical Trial Update I, European Society of Cardiology Congress, 2007, 1-5 September,

  • Audio Journal of Cardiovascular Medicine: Reduced Mortality and Repeat MI with Enoxaparin for Patients with ST Elevation Myocardial Infarction">Audio Journal of Cardiovascular Medicine: Reduced Mortality and Repeat MI with Enoxaparin for Patients with ST Elevation Myocardial Infarction
  • HARVEY WHITE, Auckland City Hospital, New Zealand REFERENCE: European Heart Journal Advanced On-Line Publication April 24th, 2007 Enoxaparin could be the new

  • Maraviroc: New Antiretroviral Drug Shows Efficacy and Safety
  • HOWARD MAYER, Pfizer Global Research, New London CT MARK WAINBERG, McGill University, Montreal Abstract Number: 104aLB, 104bLB, 14th Conference on Retroviruses and

    Post a comment